Product Candidates

Wholly owned and partnered programs spanning in vivo genome engineering and cell therapy

PIPELINE OVERVIEW

Click any program for details on the target, indication, ongoing study and upcoming milestones.

Target
Indication
Study
Preclinical Phase 1 Phase 2 ¹
Upcoming expected milestones
Fully owned

.HEAL-101
APOC3

sHTG

Planned Phase 1

H2 2027
Preliminary clinical data

.HEAL-201
PCSK9

sHC

Planned Phase 1

H1 2028
First-in-human data

Licensed Partners

Cema-cel
CD19 ²

LBCL
(allogeneic CAR-T)

ALPHA3
NCT06500273

 

ALLO-316 ³
CD70

RCC
(allogeneic CAR-T)

TRAVERSE
NCT04696731

IOV-4001
PD-1

Melanoma
(TIL)

IOV-GM1-201
NCT05361174

Fully owned by Cellectis
Licensed to partners
Click a row for details →

¹ Phase 3 may not be required if Phase 2 is registrational. According to Allogene, ALPHA3 is a pivotal Phase 2 trial.
² Cemacabtagene ansegedleucel has been developed under a collaboration agreement between Servier and Allogene based on the Licence, Development and Commercialization Agreement signed between Cellectis and Servier. Servier grants to Allogene exclusive rights to cemacabtagene ansegedleucel in the U.S., EU and UK. The ALPHA3 study targets Large B-cell Lymphoma (LBCL)
³ ALLO-316 utilizes TALEN gene=editing technology pioneered and owned by Cellectis. Allogene has an exclusive license to the Cellectis technologies for allogeneic products directed at the CD70 target. Allogene holds global development and commercial rights for this investigational candidate.

LBCL: large B-cell lymphoma; RCC: renal cell carcinoma; sHTG: severe hypertriglicerydemia; sHC: severe hypercholesterolemia; TIL: tumor infiltrated lymphocytes

CLINICAL INVESTIGATION

Phases of clinical trials

PHASE I
PHASE II
PHASE III
PHASE IV
First time an experimental drug or treatment is tested in humans to examine how well the drug is tolerated.
Trials designed to examine if the drug or treatment has a clinical activity.
Trials designed to assess the treatment effect on a clinically meaningful endpoint.
Post-marketing studies to gain additional information.
PHASE I
First time an experimental drug or treatment is tested in humans to examine how well the drug is tolerated.
PHASE II
Trials designed to examine if the drug or treatment has a clinical activity.
PHASE III
Trials designed to assess the treatment effect on a clinically meaningful endpoint.
PHASE IV
Post-marketing studies to gain additional information.

Discover the science behind our pipeline.

READ OUR SCIENCE
INVESTOR RELATIONS